Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia

De-liang Liu; Li-jun Xu; Hui Dong; Guang Chen; Zhao-yi Huang; Xin Zou; Kai-fu Wang; Yun-huan Luo; Fu-er Lu

doi:10.1007/s11655-014-1775-1

Your Location：

Home >

Browse articles >

Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia

OriginalPaper | Updated：2021-08-27

- Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia
- Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia
- 中国结合医学杂志（英文版） 2015年21卷第2期页码：132-138
- Affiliations：
  
  1. Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
  2. Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 81173370)
- DOI：10.1007/s11655-014-1775-1
  中图分类号：
- 纸质出版日期：2015，
  
  网络出版日期：2014-6-3，
Scan for full text
Liu, Dl., Xu, Lj., Dong, H. et al. Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia., Chin. J. Integr. Med. 21, 132–138 (2015). https://doi.org/10.1007/s11655-014-1775-1

De-liang Liu, Li-jun Xu, Hui Dong, et al. Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia[J]. Chinese Journal of Integrative Medicine, 2015,21(2):132-138.
Liu, Dl., Xu, Lj., Dong, H. et al. Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia., Chin. J. Integr. Med. 21, 132–138 (2015). https://doi.org/10.1007/s11655-014-1775-1 DOI：

De-liang Liu, Li-jun Xu, Hui Dong, et al. Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia[J]. Chinese Journal of Integrative Medicine, 2015,21(2):132-138. DOI： 10.1007/s11655-014-1775-1.

摘要

To investigate the effect and molecular mechanisms of different doses of 8-hydroxy dihydroberberine (Hdber) for the treatment of hyperlipidemia in rats. A rat model of hyperlipidemia was established by feeding rats a high-fat diet for 4 weeks in 70 rats of 80 animals

and 10 rats were randomly selected as control group. The hyperlipidemic rats were then randomly divided into the following groups: a model group (MOD); a berberine group [BBR

156 mg/(kg day)]; Hdber groups

which were treated with different doses of Hdber [78

39 and 19.5 mg/(kg day)]; and a simvastatin group [SIM

4 mg/(kg day)]. The corresponding therapy was administered to the rats of each treatment via gastric tubes. Normal animals were used as a control group. The blood levels of various lipids

including total cholesterol

triglycerides

high-density lipoprotein cholesterol

low-density lipoprotein cholesterol

free fatty acid (FFA)

apolipoprotein AI(Apo-AI) and apolipoprotein B (Apo-B) were examined. The protein expressions of low-density lipoprotein receptor (LDL-R)

sterol regulatory element-binding protein 2 (SREBP-2)

3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and proprotein convertase subtilisin/kexin type 9 (PCSK-9) in liver tissues were determined by Western blot analysis. Compared with the control group of rats

the model group demonstrated a deteriorated blood lipid profile and exhibited increased expression levels of PCSK-9 protein in their liver tissues (P<0.01). In addition

the high-fat diet decreased the expression levels of LDL-R

SREBP-2 and HMGCR proteins in murine liver tissues. However

the addition of berberine or Hdber reversed the blood lipid profile changes (P<0.05 or P<0.01)

decreased the expression levels of PCSK-9 proteins (P<0.01)

and increased the expression levels of LDL-R proteins in the hyperlipidemic rats (P<0.01). These compounds did not significantly influence the expression levels of SREBP-2 and HMGCR proteins in the hyperlipidemic rats. Hdber is effective in the treatment of hyperlipidemia in rats. The therapeutic mechanisms of Hdber may be associated with increasing the expression of LDL-R protein and decreasing the expression of PCSK-9 protein in liver tissues.

Abstract

and 10 rats were randomly selected as control group. The hyperlipidemic rats were then randomly divided into the following groups: a model group (MOD); a berberine group [BBR

156 mg/(kg day)]; Hdber groups

which were treated with different doses of Hdber [78

39 and 19.5 mg/(kg day)]; and a simvastatin group [SIM

4 mg/(kg day)]. The corresponding therapy was administered to the rats of each treatment via gastric tubes. Normal animals were used as a control group. The blood levels of various lipids

including total cholesterol

triglycerides

high-density lipoprotein cholesterol

low-density lipoprotein cholesterol

free fatty acid (FFA)

apolipoprotein AI(Apo-AI) and apolipoprotein B (Apo-B) were examined. The protein expressions of low-density lipoprotein receptor (LDL-R)

sterol regulatory element-binding protein 2 (SREBP-2)

the model group demonstrated a deteriorated blood lipid profile and exhibited increased expression levels of PCSK-9 protein in their liver tissues (P<0.01). In addition

the high-fat diet decreased the expression levels of LDL-R

SREBP-2 and HMGCR proteins in murine liver tissues. However

the addition of berberine or Hdber reversed the blood lipid profile changes (P<0.05 or P<0.01)

decreased the expression levels of PCSK-9 proteins (P<0.01)

关键词

8-hydroxy dihydroberberinehyperlipidemiaratlow-density lipoprotein receptor

Keywords

8-hydroxy dihydroberberinehyperlipidemiaratlow-density lipoprotein receptor

references

Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J 1993;125:958–1173.

Deepa PR, Varalakshmi P. Atheroprotective effect of exogenous heparin-derivative treatment on the aortic disturbances and lipoprotein oxidation in hypercholesterolemic diet fed rats. Clin Chim Acta 2005;355:119–130.

Glass CK, Witztum JL. Atherosclerosis, the road ahead. Cell 2001;104:503–516.

He XD, Wu HH, Lou YJ. Combined effects of atorvastatin and soybean isoflavones on hypercholesterolemia and lipoprotein metabolism. Chin J Pharmacol Toxicity (Chin) 2006;20:381–386.

Endo A, Kuroda M, Tanzawa Y. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B, fungal metabolites having hypocholesterolemic activity. 1976. Atheroscler Suppl 2004;5:39–42.

Endo A. The discovery and development of HMG-CoA reductase inhibitors. Lipid Res 2003;33:1569–1582.

Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007;9:389–396.

Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681–1690.

Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57:525–528.

Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997;46:1206–1210.

Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344–1351.

Berbeine derivatives and their producing methods, applications and their combinative usages. Patent number: 2006100194924.

Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984;76:4–12.

Duncan EA, Davé UP, Sakai J, Goldstein JL, Brown MS. Second-site cleavage in sterol regulatory element-binding protein occurs at transmembrane junction as determined by cysteinepanning. Biol Chem 1998;273:17801–17809.

Robinet P, Védie B, Chironi G, Gariépy J, Simon A, Moatti N, et al. Characterization of polymorphic structure of SREBP-2 gene: role in atherosclerosis. Atherosclerosis 2003;168:381–387.

Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab 2008;19:65–73.

Miserez AR, Muller PY, Barella L, Barella S, Staehelin HB, Leitersdorf E, et al. Sterol-regulatory elementbinding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia. Atherosclerosis 2002;164:15–26.

Zhang R. Research progress on low-density lipoprotein receptor and its regulating mechanism. Foreign Med Sci: Geriatr (Chin) 2009;3:29–30.

Marianne A, Mathilde V, Jean-Pierre R, Delphine A, Khadija O, Martine D, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154–156.

Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL-cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37:161–165.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Effects of Xuezhikang capsule on blood lipids, platelet activation and coagulation-fibrinolysis activity in patients with hyperlipidemia

Study on acupuncture parameters impacting on the acupuncture effect using cluster analysis in a rat model with middle cerebral artery occlusion

Qindan capsule (芩丹胶囊) changes adventitial collagen synthesis in spontaneously hypertensive rats

Regulation of C-type natriuretic peptides and natriuretic peptide receptor-B expression in diabetic rats renal treated by Tongluo Recipe (通络方)

Effect of wenhua juanbi recipe (温化蠲痹方) on proliferation and apoptosis of synoviocytes in rats with collagen-inducing arthritis